MedTrace Logo

Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study

NCT00242801 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1692

Last updated 2009-04-23

No results posted yet for this study

Summary

This study is being carried out to see if adding ZD1839 to other standard supportive care is more effective than standard supportive care alone for the treatment of patients with NSCLC whose disease has recurred after previous chemotherapy treatment.

Conditions

Interventions

DRUG

Gefitinib

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Oncology Medical Science Direction · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-07-31
Completion
2005-04-30

Countries

  • Argentina
  • Australia
  • Brazil
  • Bulgaria
  • Canada
  • Chile
  • Estonia
  • Germany
  • Greece
  • Hungary
  • India
  • Ireland
  • Latvia
  • Lithuania
  • Malaysia
  • Mexico
  • Netherlands
  • Norway
  • Peru
  • Philippines
  • Poland
  • Romania
  • Russia
  • Singapore
  • Slovakia
  • Sweden
  • Taiwan
  • Thailand
  • Turkey (Türkiye)
  • Ukraine
  • United Kingdom
  • Venezuela

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00242801 on ClinicalTrials.gov